Vivoryon Therapeutics (VVY) will publish its third-quarter 2026 financial results and a business update on November 5, 2026. The results cover the period ended September 30, 2026, and the update will include revised cash runway guidance.
The company said its priority remains securing funding to advance varoglutamstat into a Phase 2b study in advanced diabetic kidney disease. It reported progress in partnering efforts and is in advanced negotiations with different parties for a kidney-disease partnership. Vivoryon has also implemented additional cost-saving measures aimed at preserving financial resources while pursuing partnering activities.
Vivoryon Therapeutics (VVY) shareholders approved all agenda items at the 2026 annual general meeting, including the appointment and reappointment of executive directors.
Marcus Irsfeld was appointed to the board, while Frank Weber and Michael Schaeffer were reappointed.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) announced that its 2026 Annual General Meeting will take place on Tuesday, September 29, 2026, at 11:00 a.m. CEST at the Amsterdam offices of NautaDutilh N.V. The full agenda and related documents are available on Vivoryon’s website.
Vivoryon is a clinical-stage biotechnology company developing small molecule medicines for inflammatory and fibrotic kidney disorders, including its lead candidate varoglutamstat for diabetic kidney disease.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) reported H1 2026 results with zero revenues and a net loss of EUR 3.4 million, improved from EUR 5.5 million in H1 2025, driven by lower research and development and general and administrative expenses.
Cash and cash equivalents were EUR 2.4 million at June 30, 2026, down from EUR 5.6 million at year-end 2025, with total equity at EUR 1.6 million. The company maintains guidance that existing cash will fund operations into Q4 2026, but continuation beyond that and initiation of a planned Phase 2b diabetic kidney disease (DKD) trial depend on additional financing and/or partnerships.
Vivoryon is in advanced term sheet negotiations for a potential licensing agreement for varoglutamstat in kidney disease and reports an independent assessment by a specialist kidney investor. Phase 2 data from VIVIAD and VIVA-MIND showed statistically significant kidney function (eGFR) improvements, supported by new preclinical and mechanistic findings presented at WCN 2026.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) announced it will report H1 2026 financial results and business updates for the period ended June 30, 2026 on August 6, 2026, followed by a public conference call and webcast. The company also plans to hold its 2026 Annual General Meeting at the end of September 2026.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) reported Q1 2026 results and a kidney disease pipeline update. Varoglutamstat showed statistically significant eGFR improvements in two Phase 2 studies, with pronounced effects in elderly patients with diabetes, supporting a planned Phase 2b study in stage 3b/4 DKD, subject to new funding or partnerships.
Q1 2026 R&D and G&A each were EUR 0.9 million, and net loss was EUR 1.8 million. Cash and cash equivalents were EUR 4.0 million on March 31, 2026. Vivoryon reconfirmed guidance that existing cash should fund operations into Q4 2026, while actively pursuing strategic partnering and additional financing.
Vivoryon Therapeutics (VVY), a clinical-stage company developing small molecule medicines for inflammatory and fibrotic disorders focused on kidney diseases, will publish its Q1 2026 financial results for the period ended March 31, 2026 on Thursday, June 11, 2026.
The next financial and business update conference call/webcast is planned with the H1 2026 results, anticipated in August.
Vivoryon Therapeutics (Euronext: VVY) reported full-year 2025 results and a business update on April 23, 2026. Key highlights: varoglutamstat showed consistent eGFR benefit in two Phase 2 studies; a U.S. composition-of-matter patent runs through 2044; private placement raised €5.1M; cash of €5.6M; runway into Q4 2026.
The company plans a focused Phase 2b in stage 3b/4 DKD subject to funding or partnership and continues preclinical and MOA work supporting QPCT/L inhibition.
Vivoryon Therapeutics (Euronext: VVY) will report its full year 2025 financial results and business updates on April 23, 2026. The company will host a public conference call and webcast on April 23, 2026 at 3:00 pm CEST / 9:00 am EDT.
Investors can download the report and access the live audio webcast from Vivoryon’s investor website. Telephone participation requires pre-registration to receive dial-in details; attendees are advised to join 15 minutes early.
Vivoryon Therapeutics (Euronext: VVY) announced management will attend the Van Lanschot Kempen Life Sciences Conference on April 16, 2026 in Amsterdam.
Attendee: Julia Neugebauer, PhD, COO. The participation signals management engagement with investors and analysts at the event.